BeiGene, Ltd. (“BeiGene”) is a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer. BeiGene has a broad portfolio consisting of six internally-developed, clinical-stage, drug candidates, including three late-stage clinical drug candidates, zanubrutinib (BTK inhibitor), tislelizumab (PD-1 antibody), and pamiparib (PARP inhibitor). BeiGene has also in-licensed six drugs and drug candidates, including three marketed drugs in China ABRAXANE®, REVLIMID® and VIDAZA® under an exclusive license from Celgene Corporation, and two clinical-stage drug candidates with development and commercialization rights in China and other selected countries in the Asia-Pacific region. BeiGene was established in Beijing in 2010 and listed on the U.S. NASDAQ Global Select Market in February 2016. As of February 27, 2019, the Company had a global team of over 2,200 employees. BeiGene operates as a fully-integrated global biotechnology company with broad capabilities, both in China and globally, spanning research, clinical development, manufacturing and commercialization. Source
No articles found.
GuruMD directs patients away from costly emergency rooms and urgent cares by provi...
GuruMD directs patients away from costly emerge...
Restance is pursuing several business lines in the growing economies of East Afric...
Restance is pursuing several business lines in ...
Quanterix is a company that is digitizing biomarker analysis with the goal of adva...
Quanterix is a company that is digitizing bioma...
We are a vertically integrated commercial biopharmaceutical company that develops,...
We are a vertically integrated commercial bioph...
With a focus on the development of small molecule drugs for the treatment of cance...
With a focus on the development of small molecu...
Conatus Pharmaceuticals is a biotechnology company focused on the development and ...
Conatus Pharmaceuticals is a biotechnology comp...
Progenics develops innovative medicines and other technologies to target and treat...
Progenics develops innovative medicines and oth...
Join the National Investor Network and get the latest information with your interests in mind.